中国临床药理学与治疗学2025，Vol.30Issue(12)：1625-1631,7.DOI:10.12092/j.issn.1009-2501.2025.12.005
促觉醒药物用于阻塞性睡眠呼吸暂停残余日间过度思睡的进展
Advances in wake-promoting agents for residual excessive daytime sleepiness in obstructive sleep apnea
摘要
Abstract
Obstructive sleep apnea(OSA)is a common sleep-related breathing disorder,and ex-cessive daytime sleepiness(EDS)is one of its hall-mark clinical manifestations,impairing quality of life and increasing public-safety risks such as road traf-fic accidents.A considerable proportion of patients continue to experience residual EDS despite ade-quate treatment with continuous positive airway pressure(CPAP).This review summarizes research over the past decade on wake-promoting agents for OSA-related EDS,synthesizing clinical evidence for modafinil,armodafinil,solriamfetol,and pitolisant.Across randomized controlled trials and observa-tional studies,wake-promoting agents improve sub-jective sleepiness(Epworth Sleepiness Scale,ESS)and objective wakefulness(Maintenance of Wake-fulness Test,MWT);recently approved agents agents such as solriamfetol and pitolisant demon-strate overall favorable efficacy and safety profiles compared with traditional options.Subgroup analy-ses indicate that benefits can be observed irrespec-tive of adherence to primary OSA therapy.Impor-tantly,wake-promoting agents are adjunctive,symp-tomatic treatments for EDS and do not replace CPAP or other etiologic therapies;evaluation should ex-clude alternative causes of sleepiness prior to initia-tion,and patients should continue standard OSA management throughout treatment.关键词
阻塞性睡眠呼吸暂停/日间过度思睡/索安非托/替洛利生/促觉醒药物Key words
obstructive sleep apnea/excessive daytime sleepiness/solriamfetol/pitolisant/wake-promoting agents分类
医药卫生引用本文复制引用
欧琼,周若菡,蔡洧丹..促觉醒药物用于阻塞性睡眠呼吸暂停残余日间过度思睡的进展[J].中国临床药理学与治疗学,2025,30(12):1625-1631,7.基金项目
国家科技部科技基础资源调查专项(2022FY100803) （2022FY100803）
国家自然科学基金项目(82470083) （82470083）
